Clinical Trial Update: Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 rollover study of cenicriviroc for liver fibrosis in nonalcoholic steatohepatitis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cenicriviroc (cenicriviroc)

Snippet

Sponsor: Tobira Therapeutics, Inc. | Conditions: Nonalcoholic Steatohepatitis, Liver Cirrhosis | Phase 2 | Status: TERMINATED | Results posted: 2022-02-02